LncRNA MEG3 Reduces the Ratio of M2/M1 Macrophages Through the HuR/CCL5 Axis in Hepatocellular Carcinoma

References

• Brown ZJ, Tsilimigras DI, Ruff SM, et al. Management of hepatocellular carcinoma: a review. JAMA Surg. 2023;158(4):410–420. doi:10.1001/jamasurg.2022.7989
   PubMed Web of Science ®Google Scholar
• Jiang H, Cao H-J, Ma N, et al. Chromatin remodeling factor ARID2 suppresses hepatocellular carcinoma metastasis via DNMT1-Snail axis. Proc Natl Acad Sci U S A. 2020;117(9):4770–4780. doi:10.1073/pnas.1914937117
   PubMed Web of Science ®Google Scholar
• Li X, Wang J. Mechanical tumor microenvironment and transduction: cytoskeleton mediates cancer cell invasion and metastasis. Int J Biol Sci. 2020;16(12):2014–2028. doi:10.7150/ijbs.44943
   PubMed Web of Science ®Google Scholar
• Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression. Cancer Res. 2019;79(18):4557–4566. doi:10.1158/0008-5472.CAN-18-3962
   PubMed Web of Science ®Google Scholar
• Arneth B. Tumor Microenvironment. Medicina. 2019;56(1):1. doi:10.3390/medicina56010015
   PubMedGoogle Scholar
• Oura K, Morishita A, Tani J, et al. Tumor immune microenvironment and immunosuppressive therapy in hepatocellular carcinoma: a review. Int J Mol Sci. 2021;22(11):5801. doi:10.3390/ijms22115801
   PubMed Web of Science ®Google Scholar
• Yin Z, Huang J, Ma T, et al. Macrophages activating chemokine (C-X-C motif) ligand 8/miR-17 cluster modulate hepatocellular carcinoma cell growth and metastasis. Am J Transl Res. 2017;9(5):2403–2411.
   PubMed Web of Science ®Google Scholar
• Arvanitakis K, Koletsa T, Mitroulis I, et al. Tumor-associated macrophages in hepatocellular carcinoma pathogenesis, prognosis and therapy. Cancers. 2022;14(1):226. doi:10.3390/cancers14010226
   PubMed Web of Science ®Google Scholar
• Hilmi M, Neuzillet C, Calderaro J, et al. Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions. J Immunother Cancer. 2019;7(1):333. doi:10.1186/s40425-019-0824-5
   PubMed Web of Science ®Google Scholar
• Zhou D, Luan J, Huang C, et al. Tumor-associated macrophages in hepatocellular carcinoma: friend or foe? Gut Liver. 2021;15(4):500–516. doi:10.5009/gnl20223
   PubMed Web of Science ®Google Scholar
• Han S, Bao X, Zou Y, et al. d -lactate modulates M2 tumor-associated macrophages and remodels immunosuppressive tumor microenvironment for hepatocellular carcinoma. Sci Adv. 2023;9(29):eadg2697. doi:10.1126/sciadv.adg2697
   PubMed Web of Science ®Google Scholar
• Liu B, Yao P, Xiao F, et al. MYBL2-induced PITPNA-AS1 upregulates SIK2 to exert oncogenic function in triple-negative breast cancer through miR-520d-5p and DDX54. J Transl Med. 2021;19(1):333. doi:10.1186/s12967-021-02956-6
   PubMed Web of Science ®Google Scholar
• Lu L, Huang J, Mo J, et al. Exosomal lncRNA TUG1 from cancer-associated fibroblasts promotes liver cancer cell migration, invasion, and glycolysis by regulating the miR-524-5p/SIX1 axis. Cell Mol Biol Lett. 2022;27(1):17. doi:10.1186/s11658-022-00309-9
   PubMed Web of Science ®Google Scholar
• Liu S, Bu X, Kan A, et al. SP1-induced lncRNA DUBR promotes stemness and oxaliplatin resistance of hepatocellular carcinoma via E2F1-CIP2A feedback. Cancer Lett. 2022;528:16–30. doi:10.1016/j.canlet.2021.12.026
   PubMed Web of Science ®Google Scholar
• Tao L, Li D, Mu S, et al. LncRNA MAPKAPK5_AS1 facilitates cell proliferation in hepatitis B virus -related hepatocellular carcinoma. Lab Invest. 2022;102(5):494–504. doi:10.1038/s41374-022-00731-9
   PubMed Web of Science ®Google Scholar
• Xia A, Yuan W, Wang Q, et al. The cancer-testis lncRNA lnc-CTHCC promotes hepatocellular carcinogenesis by binding hnRNP K and activating YAP1 transcription. Nat Cancer. 2022;3(2):203–218. doi:10.1038/s43018-021-00315-4
   PubMedGoogle Scholar
• Shen C, Li J, Zhang Q, et al. LncRNA GASAL1 promotes hepatocellular carcinoma progression by up-regulating USP10-stabilized PCNA. Exp Cell Res. 2022;415(1):112973. doi:10.1016/j.yexcr.2021.112973
   PubMed Web of Science ®Google Scholar
• Wang X, Zhou Y, Dong K, et al. Exosomal lncRNA HMMR-AS1 mediates macrophage polarization through miR-147a/ARID3A axis under hypoxia and affects the progression of hepatocellular carcinoma. Environ Toxicol. 2022;37(6):1357–1372. doi:10.1002/tox.23489
   PubMed Web of Science ®Google Scholar
• Chen C, He W, Huang J, et al. LNMAT1 promotes lymphatic metastasis of bladder cancer via CCL2 dependent macrophage recruitment. Nat Commun. 2018;9(1):3826. doi:10.1038/s41467-018-06152-x
   PubMed Web of Science ®Google Scholar
• Huang JK, Ma L, Song W-H, et al. LncRNA-MALAT1 promotes angiogenesis of thyroid cancer by modulating tumor-associated macrophage FGF2 protein secretion. J Cell Biochem. 2017;118(12):4821–4830. doi:10.1002/jcb.26153
   PubMed Web of Science ®Google Scholar
• Wang X, Song X, Glass CK, et al. The long arm of long noncoding RNAs: roles as sensors regulating gene transcriptional programs. Cold Spring Harb Perspect Biol. 2011;3(1):a003756. doi:10.1101/cshperspect.a003756
   PubMed Web of Science ®Google Scholar
• Vance KW, Ponting CP. Transcriptional regulatory functions of nuclear long noncoding RNAs. Trends Genet. 2014;30(8):348–355. doi:10.1016/j.tig.2014.06.001
   PubMed Web of Science ®Google Scholar
• Shi X, Sun M, Liu H, et al. Long non-coding RNAs: a new frontier in the study of human diseases. Cancer Lett. 2013;339(2):159–166. doi:10.1016/j.canlet.2013.06.013
   PubMed Web of Science ®Google Scholar
• Tian X, Wu Y, Yang Y, et al. Long noncoding RNA LINC00662 promotes M2 macrophage polarization and hepatocellular carcinoma progression via activating Wnt/β-catenin signaling. Mol Oncol. 2020;14(2):462–483. doi:10.1002/1878-0261.12606
   PubMed Web of Science ®Google Scholar
• Li DQ, Ding Y-R, Che J-H, et al. Tumor suppressive lncRNA MEG3 binds to EZH2 and enhances CXCL3 methylation in gallbladder cancer. Neoplasma. 2022;69(3):538–549. doi:10.4149/neo_2022_210726N1046
   PubMed Web of Science ®Google Scholar
• Zheng Q, Lin Z, Xu J, et al. Long noncoding RNA MEG3 suppresses liver cancer cells growth through inhibiting β-catenin by activating PKM2 and inactivating PTEN. Cell Death Dis. 2018;9(3):253. doi:10.1038/s41419-018-0305-7
   PubMedGoogle Scholar
• Yang Z, Wang Z, Duan Y. LncRNA MEG3 inhibits non-small cell lung cancer via interaction with DKC1 protein. Oncol Lett. 2020;20(3):2183–2190. doi:10.3892/ol.2020.11770
   PubMed Web of Science ®Google Scholar
• Chen PY, Hsieh P-L, Peng C-Y, et al. LncRNA MEG3 inhibits self-renewal and invasion abilities of oral cancer stem cells by sponging miR-421. J Formos Med Assoc. 2021;120(4):1137–1142. doi:10.1016/j.jfma.2020.09.006
   PubMed Web of Science ®Google Scholar
• Ma B, Gao Z, Lou J, et al. Long non‑coding RNA MEG3 contributes to cisplatin‑induced apoptosis via inhibition of autophagy in human glioma cells. Mol Med Rep. 2017;16(3):2946–2952. doi:10.3892/mmr.2017.6897
   PubMed Web of Science ®Google Scholar
• Wang P, Chen D, Ma H, et al. LncRNA MEG3 enhances cisplatin sensitivity in non-small cell lung cancer by regulating miR-21-5p/SOX7 axis. Onco Targets Ther. 2017;10:5137–5149. doi:10.2147/OTT.S146423
   PubMed Web of Science ®Google Scholar
• Zhang Y, Liu J, Lv Y, et al. LncRNA meg3 suppresses hepatocellular carcinoma in vitro and vivo studies. Am J Transl Res. 2019;11(7):4089–4099.
   PubMed Web of Science ®Google Scholar
• Jakstaite A, Maziukiene A, Silkuniene G, et al. HuR mediated post-transcriptional regulation as a new potential adjuvant therapeutic target in chemotherapy for pancreatic cancer. World J Gastroenterol. 2015;21(46):13004–13019. doi:10.3748/wjg.v21.i46.13004
   PubMed Web of Science ®Google Scholar
• Blanco FF, Jimbo M, Wulfkuhle J, et al. The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer cells. Oncogene. 2016;35(19):2529–2541. doi:10.1038/onc.2015.325
   PubMed Web of Science ®Google Scholar
• Liu R, Wu K, Li Y, et al. Human antigen R: a potential therapeutic target for liver diseases. Pharmacol Res. 2020;155:104684. doi:10.1016/j.phrs.2020.104684
   PubMed Web of Science ®Google Scholar
• Pu J, Zhang Y, Wang A, et al. ADORA2A-AS1 restricts hepatocellular carcinoma progression via binding HuR and Repressing FSCN1/AKT axis. Front Oncol. 2021;11:754835. doi:10.3389/fonc.2021.754835
   PubMed Web of Science ®Google Scholar
• Latorre E, Carelli S, Raimondi I, et al. The ribonucleic complex HuR-MALAT1 represses CD133 expression and suppresses epithelial-mesenchymal transition in breast cancer. Cancer Res. 2016;76(9):2626–2636. doi:10.1158/0008-5472.CAN-15-2018
   PubMed Web of Science ®Google Scholar
• Zhou HJ, Wang L-Q, Zhan R-Y, et al. lncRNA MEG3 restrained the M1 polarization of microglia in acute spinal cord injury through the HuR/A20/NF-axis. Brain Pathol. 2022;32(5):e13070. doi:10.1111/bpa.13070
   PubMed Web of Science ®Google Scholar
• Huang R, Guo L, Gao M, et al. Research trends and regulation of CCL5 in prostate cancer. Onco Targets Ther. 2021;14:1417–1427. doi:10.2147/OTT.S279189
   PubMed Web of Science ®Google Scholar
• Aldinucci D, Borghese C, Casagrande N. The CCL5/CCR5 axis in cancer progression. Cancers. 2020;12(7):1765. doi:10.3390/cancers12071765
   PubMed Web of Science ®Google Scholar
• Brauß TF, Winslow S, Lampe S, et al. The RNA-binding protein HuR inhibits expression of CCL5 and limits recruitment of macrophages into tumors. Mol, Carcinog. 2017;56(12):2620–2629. doi:10.1002/mc.22706
   PubMed Web of Science ®Google Scholar
• Toda G, Yamauchi T, Kadowaki T, et al. Preparation and culture of bone marrow-derived macrophages from mice for functional analysis. STAR Protoc. 2021;2(1):100246. doi:10.1016/j.xpro.2020.100246
   PubMedGoogle Scholar
• Zong S, Dai W, Guo X, et al. LncRNA-SNHG1 promotes macrophage M2-like polarization and contributes to breast cancer growth and metastasis. Aging. 2021;13(19):23169–23181. doi:10.18632/aging.203609
   PubMedGoogle Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402–408. doi:10.1006/meth.2001.1262
   PubMed Web of Science ®Google Scholar
• Priyanka P, Sharma M, Das S, et al. The lncRNA HMS recruits RNA-binding protein HuR to stabilize the 3’-UTR of HOXC10 mRNA. J Biol Chem. 2021;297(2):100997. doi:10.1016/j.jbc.2021.100997
   PubMed Web of Science ®Google Scholar
• Chen J, Huang Z-B, Liao C-J, et al. LncRNA TP73-AS1/miR-539/MMP-8 axis modulates M2 macrophage polarization in hepatocellular carcinoma via TGF-β1 signaling. Cell Signal. 2020;75:109738. doi:10.1016/j.cellsig.2020.109738
   PubMed Web of Science ®Google Scholar
• Xie C, Li SY, Fang JH, Zhu Y, Yang JE. Functional long non-coding RNAs in hepatocellular carcinoma. Cancer Lett. 2021;500:281–291.
   PubMed Web of Science ®Google Scholar
• Liang ZX, Liu H-S, Wang F-W, et al. LncRNA RPPH1 promotes colorectal cancer metastasis by interacting with TUBB3 and by promoting exosomes-mediated macrophage M2 polarization. Cell Death Dis. 2019;10(11):829. doi:10.1038/s41419-019-2077-0
   PubMed Web of Science ®Google Scholar
• Arlauckas SP, Garren SB, Garris CS, et al. Arg1 expression defines immunosuppressive subsets of tumor-associated macrophages. Theranostics. 2018;8(21):5842–5854. doi:10.7150/thno.26888
   PubMed Web of Science ®Google Scholar
• Wang S, Cao M, Xu S, et al. Luteolin alters macrophage polarization to inhibit inflammation. Inflammation. 2020;43(1):95–108. doi:10.1007/s10753-019-01099-7
   PubMed Web of Science ®Google Scholar
• Chistiakov DA, Killingsworth MC, Myasoedova VA, et al. CD68/macrosialin: not just a histochemical marker. Lab Invest. 2017;97(1):4–13. doi:10.1038/labinvest.2016.116
   PubMed Web of Science ®Google Scholar
• Gan ZS, Wang -Q-Q, Li J-H, et al. Iron reduces M1 macrophage polarization in RAW264.7 Macrophages Associated with Inhibition of STAT1. Mediators Inflamm. 2017;2017:8570818. doi:10.1155/2017/8570818
   PubMed Web of Science ®Google Scholar
• Xu Y, Yu X, Xu J, et al. LncRNA RP11-138J23.1 contributes to gastric cancer progression by interacting with RNA-Binding Protein HuR. Front Oncol. 2022;12:848406. doi:10.3389/fonc.2022.848406
   PubMed Web of Science ®Google Scholar
• Hinman MN, Lou H. Diverse molecular functions of Hu proteins. Cell Mol Life Sci. 2008;65(20):3168–3181. doi:10.1007/s00018-008-8252-6
   PubMed Web of Science ®Google Scholar
• Candido J, Hagemann T. Cancer-related inflammation. J Clin Immunol. 2013;33(Suppl 1):S79–84. doi:10.1007/s10875-012-9847-0
   PubMed Web of Science ®Google Scholar
• Liu C, Yao Z, Wang J, et al. Macrophage-derived CCL5 facilitates immune escape of colorectal cancer cells via the p65/STAT3-CSN5-PD-L1 pathway. Cell Death Differ. 2020;27(6):1765–1781. doi:10.1038/s41418-019-0460-0
   PubMed Web of Science ®Google Scholar
• Xu H, Zhao J, Li J, et al. Cancer associated fibroblast-derived CCL5 promotes hepatocellular carcinoma metastasis through activating HIF1α/ZEB1 axis. Cell Death Dis. 2022;13(5):478. doi:10.1038/s41419-022-04935-1
   PubMed Web of Science ®Google Scholar
• Walens A, DiMarco AV, Lupo R, Kroger BR, Damrauer JS, Alvarez JV. CCL5 promotes breast cancer recurrence through macrophage recruitment in residual tumors. Elife. 2019;8:e43653.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Marchesi F, et al. Macrophages as tools and targets in cancer therapy. Nat Rev Drug Discov. 2022;21(11):799–820. doi:10.1038/s41573-022-00520-5
   PubMed Web of Science ®Google Scholar
• Chen S, Saeed AFUH, Liu Q, et al. Macrophages in immunoregulation and therapeutics. Signal Transduct Target Ther. 2023;8(1):207. doi:10.1038/s41392-023-01452-1
   PubMed Web of Science ®Google Scholar